Evaxion A/S (EVAX) stock
EVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.54−0.24 (-8.63%)
Close on Nov 18, 2026Market cap $21.18MP/E –Yield –
Evaxion A/S net income
Net income is the profit left for shareholders after every expense, interest and tax.
Evaxion A/S's net income for the twelve months ending Jun 30, 2022 was -$24.18M. For fiscal 2025 it was -$7.71M. The highest annual figure on record is -$5.54M in fiscal 2018.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$7.71M | – |
| FY2024 | Dec 31, 2024 | -$10.57M | – |
| FY2023 | Dec 31, 2023 | -$22.13M | – |
| FY2022 | Dec 31, 2022 | -$23.17M | – |
| FY2021 | Dec 31, 2021 | -$24.53M | – |
| FY2020 | Dec 31, 2020 | -$15.02M | – |
| FY2019 | Dec 31, 2019 | -$11.20M | – |
| FY2018 | Dec 31, 2018 | -$5.54M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.73M | – |
| Q2 FY2025 | Jun 30, 2025 | -$4.83M | – |
| Q2 FY2024 | Jun 30, 2024 | -$6.20M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.68M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.77M | – |
| Q1 FY2022 | Mar 31, 2022 | -$5.79M | – |
| Q4 FY2021 | Dec 31, 2021 | -$8.37M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.25M | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.82M | – |
| Q1 FY2021 | Mar 31, 2021 | -$4.09M | – |
| Q4 FY2020 | Dec 31, 2020 | -$4.27M | – |
| Q3 FY2020 | Sep 30, 2020 | -$4.01M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.64M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.10M | – |
See a number that looks wrong?